Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial.

J Immunother Cancer · 2025 · PMC11979599 · PMID 40199609

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significancep = 0.056so close (0.05 < p ≤ 0.1)

showed a trendno p-value reported

Similarly, patients with liver metastasis showed a trend toward poorer survival, although this did not reach statistical significance (median OS 7.9 months vs 20.2, HR=2.61, 95% CI 0.72 to 9.17, p = 0.056, online supplemental figure S2B ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.